Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

36.72USD
18 Sep 2019
Change (% chg)

$0.14 (+0.38%)
Prev Close
$36.58
Open
$36.72
Day's High
$36.72
Day's Low
$36.72
Volume
1,311
Avg. Vol
201,394
52-wk High
$79.14
52-wk Low
$33.17

Latest Key Developments (Source: Significant Developments)

Agios Pharmaceuticals Inc Reports Q1 Loss Per Share Of $1.59
Thursday, 2 May 2019 

May 2 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS BUSINESS HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.AGIOS PHARMACEUTICALS INC - TOTAL REVENUE FOR Q1 OF 2019 WAS $30.2 MILLION COMPARED TO REVENUE OF $8.8 MILLION FOR Q1 OF 2018.AGIOS PHARMACEUTICALS - CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AS OF MARCH 31, 2019 WERE $707.8 MILLION COMPARED TO $805.4 MILLION AS OF DEC 31, 2018.AGIOS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $1.59.AGIOS PHARMACEUTICALS INC - MARCH 31, 2019 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WAS $707.8M; PROVIDES RUNWAY THROUGH AT LEAST END OF 2020.  Full Article

Agios Reports Updated Data From Phase 1 Study Of Ivosidenib In Combination With Azacitidine
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS UPDATED DATA FROM PHASE 1 STUDY OF IVOSIDENIB IN COMBINATION WITH AZACITIDINE DEMONSTRATING DEEP AND DURABLE RESPONSES IN NEWLY DIAGNOSED IDH1 MUTANT ACUTE MYELOID LEUKEMIA (AML) PATIENTS.AGIOS PHARMACEUTICALS INC - OVERALL RESPONSE RATE OF 78%, CR+CRH RATE OF 65% AND 12-MONTH SURVIVAL RATE OF 82%.AGIOS PHARMACEUTICALS INC - MEAN NEUTROPHIL AND PLATELET COUNTS WERE MAINTAINED NEAR OR ABOVE CRH THRESHOLDS WHILE ON STUDY TREATMENT.AGIOS PHARMA - SAFETY PROFILE OF COMBINATION THERAPY REMAINS CONSISTENT WITH SAFETY PROFILE OF IVOSIDENIB AND AZACITIDINE ALONE IN PATIENT POPULATION.  Full Article

Agios Highlights Key 2019 Initiatives To Broaden Potential For Cancer And Rare Genetic Disease Programs
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS HIGHLIGHTS KEY 2019 INITIATIVES TO BROADEN POTENTIAL FOR CANCER AND RARE GENETIC DISEASE PROGRAMS TO BUILD LONG-TERM VALUE.AGIOS PHARMACEUTICALS - ENDED 2018 WITH ABOUT $805 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.AGIOS - EXPECTS CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF DEC 31, 2018 TO FUND ANTICIPATED OPERATING EXPENSES THROUGH AT LEAST END OF 2020.  Full Article

FDA Says Symptoms Of Differentiation Syndrome Are Not Being Recognized With Idhifa
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - U.S. Food and Drug Administration::FDA WARNS THAT SYMPTOMS OF A SERIOUS CONDITION AFFECTING THE BLOOD CELLS ARE NOT BEING RECOGNIZED WITH THE LEUKEMIA MEDICINE IDHIFA (ENASIDENIB).FDA - IDHIFA PRESCRIBING INFORMATION AND PATIENT MEDICATION GUIDE ALREADY CONTAIN A WARNING ABOUT DIFFERENTIATION SYNDROME..FDA - BECOME AWARE OF CASES OF DIFFERENTIATION SYNDROME IN PATIENTS RECEIVING IDHIFA NOT BEING RECOGNIZED, PATIENTS NOT RECEIVING NECESSARY TREATMENT.FDA - IDHIFA IS MANUFACTURED FOR AND MARKETED BY CELGENE, LICENSED FROM AGIOS PHARMACEUTICALS.FDA - HEALTH CARE PROFESSIONALS SHOULD ALSO BE VIGILANT IN MONITORING FOR DIFFERENTIATION SYNDROME WHEN PRESCRIBING AGIOS' TIBSOVO.  Full Article

Agios Pharmaceuticals - Co, Celgene Agreed To Terminate Collaboration, License Deal
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC - ON SEPT 4, CO, CELGENE AGREED TO TERMINATE COLLABORATION AND LICENSE DEAL DATED APRIL 27, 2015 BETWEEN CO AND CELGENE.AGIOS PHARMA- FOR SPECIFIED PERIOD CELGENE SHALL BE PROHIBITED FROM DEVELOPING, COMMERCIALIZING PRODUCT THAT INHIBITS ISOCITRATE DEHYDROGENASE 1.AGIOS - ON SEPT 4, CO, CELGENE ALSO AGREED TO TERMINATE LICENSE AGREEMENT DATED APRIL 27, 2015 BETWEEN CO'S UNIT AND CELGENE INTERNATIONAL II SARL.AGIOS PHARMACEUTICALS INC - PROHIBITED PRODUCTS APPLY FOR INHIBITS ISOCITRATE DEHYDROGENASE 1 AT SPECIFIED LEVELS OF BINDING FOR ANY INDICATION.AGIOS PHARMACEUTICALS INC - COMPANY SHALL BE PROHIBITED FROM DEVELOPING, MANUFACTURING OR COMMERCIALIZING AG-881 IN HEMATOLOGIC INDICATIONS.AGIOS PHARMACEUTICALS - FROM & AFTER AG-881 AGREEMENT TERMINATION DATE, CO TO OBTAIN SOLE GLOBAL RIGHTS TO AG-881 - SEC FILING.AGIOS PHARMACEUTICALS - NO PARTY TO HAVE FINANCIAL OBLIGATION TO OTHER PARTIES, INCLUDING MILESTONES, ROYALTIES, OTHER PAYMENTS AFTER TERMINATION DATE.  Full Article

Agios Announces Chief Executive Officer Succession Plan
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES CHIEF EXECUTIVE OFFICER SUCCESSION PLAN.AGIOS PHARMACEUTICALS SAYS CURRENT CEO DAVID SCHENKEIN TO BECOME EXECUTIVE CHAIRMAN, EFFECTIVE FEB 1, 2019.AGIOS PHARMACEUTICALS SAYS JACQUALYN FOUSE TO SUCCEED SCHENKEIN AS CEO; FOUSE WILL REMAIN MEMBER OF BOARD.AGIOS PHARMACEUTICALS SAYS CURRENT CHAIRMAN JOHN MARAGANORE WILL TRANSITION TO DIRECTOR OF BOARD, EFFECTIVE FEB 1, 2019.  Full Article

Agios Q2 Revenue $40.4 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $40.4 MILLION.Q2 REVENUE VIEW $11.3 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $1.19.  Full Article

FDA Says Tibsovo's Prescribing Information Includes Boxed Warning Regarding Differentiation Syndrome
Friday, 20 Jul 2018 

July 20 (Reuters) - U.S. Food and Drug Administration::FDA SAYS TIBSOVO'S PRESCRIBING INFORMATION INCLUDES BOXED WARNING THAT A POTENTIALLY FATAL ADVERSE REACTION KNOWN AS DIFFERENTIATION SYNDROME CAN OCCUR.  Full Article

Agios Pharmaceuticals Says FDA Grants Approval Of Tibsovo
Friday, 20 Jul 2018 

July 20 (Reuters) - Agios Pharmaceuticals Inc ::FDA GRANTS APPROVAL OF TIBSOVO®, THE FIRST ORAL, TARGETED THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS - TIBSOVO, AN ORAL, TARGETED INHIBITOR OF IDH1 ENZYME, IS FIRST FDA-APPROVED THERAPY FOR PATIENTS WITH R/R AML & AN IDH1 MUTATION.  Full Article

Agios Announces Proposed Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING.SAYS ALL OF SHARES IN OFFERING ARE TO BE SOLD BY AGIOS.  Full Article